ストックスクリーナーアプリを入手
0.40
60.78%
-0.62
アフターアワーズ：
.40
Moleculin Biotech Inc (MBRX) 最新ニュース
MBRX|Moleculin Biotech Inc|Price:2.190|Chg%:+0.070 - TradingKey
Moleculin Biotech Inc (MBRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Moleculin Biotech, Inc. Revenue Breakdown – NASDAQ:MBRX - TradingView
TradingKey - TradingKey
Enterprise value to EBIT forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:-0.030 - TradingKey
Moleculin Biotech Inc (MBRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Moleculin Biotech Inc (MBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Moleculin Biotech Inc (MBRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Moleculin Biotech Inc (MBRX) Institutional Confidence - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.150|Chg%:+0.030 - TradingKey
MBRX|Moleculin Biotech Inc|Price:2.160|Chg%:+0.040 - TradingKey
Moleculin Biotech Inc (MBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Moleculin Biotech Inc (MBRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MBRX stock trades around recent lows as Moleculin focuses on cash runway and clinical progress - Ad-hoc-news.de
MBRX stock holds the line as Moleculin advances its pipeline - Ad-hoc-news.de
MBRX Q1 2026 Earnings: Wider-Than-Expected Loss Reflects Continued R&D InvestmentHealthcare Earnings Report - dars.gov.et
Why Did MBRX Stock Climb 14% Today? - Stocktwits
Enterprise value to revenue forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to sales forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Price to book forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
Moleculin Biotech (MBRX) Weakens: Stock Drops 6.56% as Key Support Levels TestedTrend Reversal Picks - dars.gov.et
Enterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRX - TradingView
Price to earnings forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech focuses on oncology pipeline and Nasdaq listing - ad-hoc-news.de
Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor 'What This Means' Segment - marketscreener.com
Moleculin CEO discusses preliminary results from leukemia trial By Investing.com - Investing.com Australia
Moleculin CEO discusses preliminary results from leukemia trial - Investing.com
Moleculin reports positive early results from P... - Pluang
Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment - Quiver Quantitative
Moleculin CEO, Walter Klemp, Highlights Positive - GlobeNewswire
Moleculin Biotech (MBRX) Shares Slide 9% as Stock Approaches Key Support LevelVolume Breakout Ideas - dars.gov.et
Moleculin Biotech | 8-K: Current report - Moomoo
MBRXMoleculin Biotech Inc Dividends - Finviz
Maxim Group Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $10 - Moomoo
What Do MoonLake's Latest Week 40 HS Results Really Mean for Investors - Kavout | AI
Why is Moleculin stock falling today? - MSN
Moleculin Biotech (MBRX) Plunges 25% as Key Support Nears—What’s Behind the Sharp DeclineATR Stop - dars.gov.et
MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance - Asianet Newsable
Moleculin Biotech, Inc. Financial Disclosures & Filings - TradingView
Why is Moleculin Stock Falling Today? - Benzinga
H.C. Wainwright Maintains Moleculin Biotech(MBRX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Moleculin Biotech (MBRX) Reports Positive Efficacy Results in Ph - GuruFocus
Moleculin Biotech, Inc. (Moleculin) recently announced the interim analysis results of its phase 2/3 "Miracle" clinical trial, showing positive data. - Bitget
Moleculin reports positive interim data from AML trial - Investing.com
Moleculin Biotech Updates Investors With New Presentation - TipRanks
Moleculin Biotech Reports Promising Annamycin AML Trial Data - TipRanks
Moleculin Biotech, Inc. Shares June 2026 Investor Presentation and Key Regulatory Updates - Minichart
Moleculin reports positive interim data from AML trial By Investing.com - Investing.com India
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control - The Manila Times
Form 8-K Moleculin Biotech, Inc. For: Jun 30 - StreetInsider
Annamycin boosts remission in Moleculin (MBRX) pivotal AML MIRACLE trial interim - Stock Titan
Moleculin Biotech (NASDAQ: MBRX) raises $2.7M as 1.36M warrants are exercised - Stock Titan
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):